Passage Bio
Philadelphia
About Passage Bio
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $379.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2021)
- Ticker: nasdaq:PASG
- Website: passagebio.com
- Phone: 267-866-0311
Industries & Categories
Biotechnology, Health Care, Therapeutics, Wellness
Social Profiles
Canonical: https://fsome.com/organization/passage-bio-85835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.